MoonLake Immunotherapeutics (MLTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 849.63M |
| Enterprise Value | 590.83M |
| P/E Ratio | -5.71 |
| PEG Ratio | 0.12 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 6.22 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -5.83 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
AD
Management Effectiveness
| Return On Assets | -0.64 |
| Return On Equity | -0.86 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -2.62M |
| EBITDA | -219.85M |
| Net Income | -227.32M |
| Diluted EPS | -3.53 |
Balance Sheet
| Total Cash | 357.92M |
| Total Cash/Share | 5.02 |
| Total Debt | 100.8M |
| Total Debt/Equity | 0.4 |
| Current Ratio | 8.6 |
| Book Value Per Share | 3.56 |
Price History
| 52-Week Change | -50.61 |
| 52-Week High | 62.75 |
| 52-Week Low | 5.95 |
| Moving Average 50 Days | 17.89 |
| Moving Average 200 Days | 18.82 |
Statistics
| Average Volume | 1M |
| Shares Outstanding | 73.62M |
| % Held by Institutions | 97.8 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
